Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Boston Scientific Corporation

Clinicaltrial registered9 Nov 2026

Boston Scientific Corporation

9 Nov 2026: Trial registered · The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
Conditions
Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation (PersAF), FARAPULSE
Phase
Not applicable
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Croatia, Czechia, France
Country
Croatia
Reference
NCT07925359
Location
Croatia, Czechia, France
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boston Scientific Corporation

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Boston Scientific Corporation in our registers.

More from Croatia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.